Related Experiment Video
Updated: May 11, 2026

Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
Published on: January 12, 2016
Targeting the CCL2/CCR2 Axis in HIV-1 Infection and Ischemic Stroke
Silvia Torices1, Daniela Iglesias Gallo1, Enrique Lara1
1Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.
Insights
People with HIV have a higher risk of ischemic stroke. The CCL2/CCR2 pathway may drive this risk and could be a therapeutic target for stroke prevention in HIV infection.
Area of Science:
- Neuroscience
- Immunology
- Infectious Diseases
Background:
- HIV infection is linked to increased cardiovascular and cerebrovascular events.
- Ischemic stroke incidence is 3 times higher in people with HIV compared to uninfected individuals.
- Mechanisms underlying enhanced ischemic stroke risk in HIV remain unclear.
Purpose of the Study:
- To review the role of the CCL2/CCR2 signaling pathway in HIV infection.
- To examine the pathway's influence on ischemic stroke outcomes and recovery.
- To propose the CCL2/CCR2 axis as a potential therapeutic target.
Main Methods:
- Literature review focusing on the CCL2/CCR2 pathway in HIV and stroke.
- Analysis of chemokine function in leukocyte recruitment and neuroinflammation.
- Examination of blood-brain barrier permeability.
Main Results:
- CCL2/CCR2 signaling mediates leukocyte (CD4+ T cells, monocytes/macrophages) recruitment to the brain.
- This pathway contributes to neuroinflammation and blood-brain barrier disruption post-stroke.
- The CCL2/CCR2 axis is implicated in the heightened stroke risk in HIV.
Conclusions:
- The CCL2/CCR2 pathway plays a significant role in the pathogenesis of ischemic stroke in HIV-infected individuals.
- Targeting the CCL2/CCR2 axis offers a promising therapeutic strategy for mitigating stroke risk and improving outcomes in people living with HIV.
Abstract:
HIV-associated comorbidities, including cardiovascular and cerebrovascular events, are frequent diseases in people living with HIV. Notably, the prevalence of ischemic stroke is 3× higher in people living with HIV than in noninfected individuals, making it one of the most significant cerebrovascular events in people living with HIV. Despite this close association, the mechanisms involved in the enhanced incidence of ischemic stroke in HIV infection remain poorly understood. A chemokine CCL2 (C-C motif chemokine ligand 2), acting via its receptor CCR2 (C-C chemokine receptor type 2), is a prominent chemoattractant involved in the recruitment of CD4+T cells and monocytes/macrophages, which are primary targets for HIV infection. Due to its role in directing leukocyte migration into the brain and enhancing blood-brain barrier permeability, CCL2 is also a critical mediator of neuroinflammation after brain damage, such as ischemic stroke. In this review, we examine the role of the CCL2/CCR2 signaling pathway in HIV infection, its influence on the progression of ischemic stroke outcome and recovery, and propose the CCL2/CCR2 axis as a possible therapeutic target in people living with HIV.
Related Concept Videos
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology

